Benzyl Isothiocyanate Inhibits Epithelial-Mesenchymal Transition in Cultured and Xenografted Human Breast Cancer Cells

被引:49
作者
Sehrawat, Anuradha [1 ]
Singh, Shivendra V. [1 ]
机构
[1] Univ Pittsburgh, Inst Canc, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA
关键词
E-CADHERIN EXPRESSION; TUMOR PROGRESSION; PREVENTION; CARCINOMA; INDUCTION; GROWTH; CHEMOPREVENTION; ANGIOGENESIS; TAMOXIFEN; APOPTOSIS;
D O I
10.1158/1940-6207.CAPR-10-0306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We showed previously that cruciferous vegetable constituent benzyl isothiocyanate (BITC) inhibits growth of cultured and xenografted human breast cancer cells and suppresses mammary cancer development in a transgenic mouse model. We now show, for the first time, that BITC inhibits epithelial-mesenchymal transition (EMT) in human breast cancer cells. Exposure of estrogen-independent MDA-MB-231 and estrogen-responsive MCF-7 human breast cancer cell lines and a pancreatic cancer cell line (PL-45) to BITC resulted in upregulation of epithelial markers (e. g., E-cadherin and/or occludin) with a concomitant decrease in protein levels of mesenchymal markers, including vimentin, fibronectin, snail, and/or c-Met. The BITC-mediated induction of E-cadherin protein was accompanied by an increase in its transcription, whereas BITC-treated MDA-MB-231 cells exhibited suppression of vimentin, snail, and slug mRNA levels. Experimental EMT induced by exposure to TGF beta and TNF alpha or Rb knockdown in a spontaneously immortalized nontumorigenic human mammary epithelial cell line (MCF-10A) was also partially reversed by BITC treatment. The TGF beta-/TNF alpha-induced migration of MCF-10A cells was inhibited in the presence of BITC, which was partially attenuated by RNA interference of E-cadherin. Inhibition of MDA-MB-231 xenograft growth in vivo in female athymic mice by BITC administration was associated with an increase in protein level of E-cadherin and suppression of vimentin and fibronectin protein expression. In conclusion, this study reports a novel anticancer effect of BITC involving inhibition of EMT, a process triggered during progression of cancer to invasive state. Cancer Prev Res; 4(7); 1107-17. (C)2011 AACR.
引用
收藏
页码:1107 / 1117
页数:11
相关论文
共 48 条
[41]   Inhibition of Human Breast Cancer Xenograft Growth by Cruciferous Vegetable Constituent Benzyl Isothiocyanate [J].
Warin, Renaud ;
Xiao, Dong ;
Arlotti, Julie A. ;
Bommareddy, Ajay ;
Singh, Shivendra V. .
MOLECULAR CARCINOGENESIS, 2010, 49 (05) :500-507
[42]   Prevention of Mammary Carcinogenesis in MMTV-neu Mice by Cruciferous Vegetable Constituent Benzyl Isothiocyanate [J].
Warin, Renaud ;
Chambers, William H. ;
Potter, Douglas M. ;
Singh, Shivendra V. .
CANCER RESEARCH, 2009, 69 (24) :9473-9480
[43]   Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells [J].
Whipple, Rebecca A. ;
Balzer, Eric M. ;
Cho, Edward H. ;
Matrone, Michael A. ;
Yoon, Jennifer R. ;
Martin, Stuart S. .
CANCER RESEARCH, 2008, 68 (14) :5678-5688
[44]   Benzyl Isothiocyanate Targets Mitochondrial Respiratory Chain to Trigger Reactive Oxygen Species-dependent Apoptosis in Human Breast Cancer Cells [J].
Xiao, Dong ;
Powolny, Anna A. ;
Singh, Shivendra V. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (44) :30151-30163
[45]   Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak [J].
Xiao, Dong ;
Vogel, Victor ;
Singh, Shivendra V. .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2931-2945
[46]   Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction [J].
Xiao, Dong ;
Lew, Karen L. ;
Kim, Young-Ae ;
Zeng, Yan ;
Hahm, Eun-Ryeong ;
Dhir, Rajiv ;
Singh, Shivendra V. .
CLINICAL CANCER RESEARCH, 2006, 12 (22) :6836-6843
[47]   A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells [J].
Zhang, Lin-lin ;
Li, Lei ;
Wu, Da-peng ;
Fan, Jin-hai ;
Li, Xiang ;
Wu, Kai-jie ;
Wang, Xin-yang ;
He, Da-lin .
ACTA PHARMACOLOGICA SINICA, 2008, 29 (09) :1060-1068
[48]  
Zhang YS, 2003, MOL CANCER THER, V2, P1045